# Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

> **NCT00923364** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- MDS
- Immunodeficiency
- GATA2

## Interventions

- **DRUG:** Cyclophosphamide (CTX, Cytoxan)
- **DRUG:** Fludarabine(Fludara,Berlex Laboratories)
- **PROCEDURE:** Total Body Irradiation (TBI)
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell (HSC)
- **DRUG:** Equine Anti-Thymocyte Globulin

## Key facts

- **NCT ID:** NCT00923364
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-07
- **Primary completion:** 2014-06-12
- **Final completion:** 2017-02-26
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923364, "Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00923364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*